close

Fenwick Represents Arcutis Biotherapeutics in $183.3 Million Initial Public Offering

February 04, 2020

​​

Elit sed vulputate mi sit amet mauris. Semper viverra nam libero justo laoreet sit. Ut placerat orci nulla pellentesque dignissim. Tincidunt eget nullam non nisi est sit. Morbi tempus iaculis urna id volutpat lacus. Suspendisse in est ante in. Integer vitae justo eget magna fermentum iaculis eu non. Eu nisl nunc mi ipsum faucibus vitae. Ut morbi tincidunt augue interdum velit euismod in pellentesque massa. Ut ornare lectus sit amet. Aenean et tortor at risus viverra adipiscing at in tellus. Dolor purus non enim praesent elementum. Viverra suspendisse potenti nullam ac. Volutpat diam ut venenatis tellus in.

Fenwick & West represented Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, in its initial public offering of 10,781,250 shares of its common stock at a price to the public of $17.00 per share, which includes 1,406,250 shares sold upon full exercise of the underwriters’ option to purchase additional shares of common stock.

The gross proceeds from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Arcutis, were approximately $183.3 million.

Goldman Sachs & Co. LLC, Cowen and Company, LLC and Guggenheim Securities, LLC acted as bookrunning managers for the proposed offering. Cantor Fitzgerald & Co. acted as lead manager fo​r the offering.

More information about the offering can be obtained from Arcutis’ announcement.

The Fenwick transaction team included corporate partners Matthew Rossiter and Robert Freedman and associates Julia Forbess, Alice Lin, Ivan Au and John Clancy; executive compensation and employee benefits partner Elizabeth Gartland and counsel Nicholas Frey; and technology transactions partner Stefano Quintini and associate Sophia Chen.

Sit amet justo donec enim diam. Condimentum mattis pellentesque id nibh tortor id. Rhoncus urna neque viverra justo nec ultrices dui sapien eget. Pellentesque habitant morbi tristique senectus et netus et malesuada fames. Ut tellus elementum sagittis vitae et. Amet justo donec enim diam vulputate ut pharetra sit. Pellentesque habitant morbi tristique senectus et netus. Ut sem viverra aliquet eget sit amet. Habitasse platea dictumst quisque sagittis purus. Diam phasellus vestibulum lorem sed risus.